仙琚制药因涉嫌垄断拟被罚没近2亿元，监管部门回应：当前案件处于行政处罚告知阶段

Core Viewpoint - Xianju Pharmaceutical is facing an administrative penalty of approximately 200 million yuan for allegedly engaging in a monopoly agreement related to the pricing of Dexamethasone Sodium Phosphate raw materials, as disclosed in its annual report [1][6]. Group 1: Administrative Penalty Details - The Tianjin Municipal Market Supervision Administration has issued a notice indicating that Xianju Pharmaceutical is suspected of reaching and implementing a monopoly agreement by fixing and changing the price of Dexamethasone Sodium Phosphate raw materials [1][6]. - The proposed administrative penalty includes the confiscation of illegal gains amounting to 23.75 million yuan and a fine of 172 million yuan, which is 8% of the company's sales in 2023, totaling approximately 195 million yuan [6]. - Xianju Pharmaceutical has acknowledged the expected liabilities and related losses in its financial statements for 2024, in accordance with the administrative penalty notice [6]. Group 2: Market Context and Impact - Dexamethasone Sodium Phosphate is widely used in clinical treatments for allergic and autoimmune inflammatory diseases, with sales in Chinese public medical institutions reaching nearly 1.2 billion yuan in 2023, reflecting a year-on-year growth of 59.27% [6]. - The sales figure for Dexamethasone Sodium Phosphate was less than 400 million yuan in 2021, indicating significant growth in demand [6]. - Xianju Pharmaceutical's total revenue for 2024 is reported at 4 billion yuan, a decrease of 2.98% year-on-year, with net profit declining by 29.46% to 397 million yuan, attributed partly to the impact of national centralized drug procurement on its products, including Dexamethasone Sodium Phosphate [8]. Group 3: Regulatory Environment - The case is currently in the administrative penalty notification stage, and the Tianjin Municipal Market Supervision Administration has stated that the details will be publicly disclosed after the case is processed [10]. - Previous cases of pharmaceutical companies facing penalties for monopolistic practices highlight a growing regulatory scrutiny in the industry, with significant fines imposed on companies for similar violations [9].